SEB Asset Management AB Makes New $86.54 Million Investment in Stryker Corporation $SYK

SEB Asset Management AB acquired a new stake in shares of Stryker Corporation (NYSE:SYK) in the 1st quarter, HoldingsChannel.com reports. The firm acquired 263,366 shares of the medical technology company’s stock, valued at approximately $86,539,000.

Several other large investors have also made changes to their positions in the business. Vanguard Group Inc. raised its holdings in shares of Stryker by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock worth $11,917,396,000 after purchasing an additional 133,892 shares during the last quarter. State Street Corp lifted its position in Stryker by 2.1% during the fourth quarter. State Street Corp now owns 15,254,407 shares of the medical technology company’s stock valued at $5,374,731,000 after purchasing an additional 311,507 shares during the period. Geode Capital Management LLC boosted its holdings in Stryker by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company’s stock valued at $2,636,238,000 after purchasing an additional 69,851 shares during the last quarter. Wellington Management Group LLP grew its position in Stryker by 22.6% during the 4th quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock worth $2,282,192,000 after purchasing an additional 1,198,665 shares during the period. Finally, Norges Bank acquired a new stake in Stryker during the 4th quarter worth about $1,822,272,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

More Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker launched Mako RPS, a new handheld robotic power system for total knee replacement, expanding its Mako robotics portfolio beyond robotic-arm assisted surgery and potentially broadening adoption of robotic-assisted orthopedic procedures. Stryker expands Mako robotics portfolio with full market release of Mako RPS
• Positive Sentiment: Media coverage highlighted the full U.S. commercial launch of Mako RPS, reinforcing investor optimism that Stryker is strengthening its competitive position in orthopedic robotics. Stryker fully launches Mako robotic power system for knee surgery in US
• Positive Sentiment: Unusually heavy call-option buying suggested traders were positioning for more upside in SYK, which can sometimes add momentum to the shares.
• Positive Sentiment: RBC Capital reiterated its Buy rating on Stryker, providing another favorable signal from the analyst community. RBC Capital Sticks to Their Buy Rating for Stryker (SYK)
• Neutral Sentiment: MarketWatch noted that Stryker stock outperformed peers on a strong trading day, indicating relative strength but without a specific new company catalyst. Stryker Corp. stock outperforms competitors on strong trading day
• Neutral Sentiment: Analyst commentary on Stryker was mixed in broader healthcare-sector coverage, but no major negative surprise was indicated in the headlines provided. Analysts Offer Insights on Healthcare Companies: Shionogi & Co (OtherSGIOF) and Stryker (SYK)

Insiders Place Their Bets

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the sale, the vice president directly owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. This trade represents a 30.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP M Kathryn Fink sold 5,220 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.85, for a total value of $1,481,697.00. Following the completion of the sale, the vice president owned 13,137 shares of the company’s stock, valued at $3,728,937.45. This trade represents a 28.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 323,264 shares of company stock worth $100,659,489. 4.60% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

SYK has been the subject of several analyst reports. Weiss Ratings cut Stryker from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 4th. Robert W. Baird set a $385.00 target price on Stryker in a report on Friday, May 1st. Wells Fargo & Company reduced their price target on Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. Leerink Partners decreased their price target on Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a report on Friday, June 5th. Finally, Argus set a $370.00 price objective on Stryker in a research report on Thursday, July 9th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Stryker presently has an average rating of “Moderate Buy” and an average target price of $392.52.

Stryker Trading Down 3.4%

Shares of Stryker stock opened at $319.78 on Friday. The firm has a 50-day simple moving average of $312.69 and a two-hundred day simple moving average of $336.82. The company has a market cap of $122.59 billion, a P/E ratio of 37.01, a price-to-earnings-growth ratio of 2.05 and a beta of 0.77. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $404.87. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The firm had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. During the same period in the previous year, the company earned $2.84 earnings per share. The company’s revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities analysts predict that Stryker Corporation will post 14.99 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be given a dividend of $0.88 per share. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s dividend payout ratio is currently 40.74%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.